ExploreWatchlistsPricing
  1. JP-listed companies
  2. Chiome Bioscience Inc.
  3. Financials
  4. Cash from operations

Chiome Bioscience Inc. (4583)

Market cap
¥6.9B
P/E ratio
Develops antibody drugs for cancer and other diseases using its ADLib® System technology, while providing antibody development services to pharmaceutical companies.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCash from operations (Million JPY)YoY (%)
Dec 31, 2025-936-6.47%
Dec 31, 2024-1,001-6.41%
Dec 31, 2023-1,069-10.23%
Dec 31, 2022-1,191+5.28%
Dec 31, 2021-1,131-16.83%
Dec 31, 2020-1,360-11.53%
Dec 31, 2019-1,537-8.96%
Dec 31, 2018-1,689+94.73%
Dec 31, 2017-867-10.59%
Dec 31, 2016-970-22.12%
Dec 31, 2015-1,245

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat